Former Head of Roche in Russia Becomes Co-Owner of Elpida

The deal, the amount of which is not disclosed, was brought to the attention of Vedomosti. In a conversation with the publication, Mikhail Burmistrov, General Director of Infoline-Analytics, estimated the market value of Elpida at 12-15 billion rubles, meaning that Milos Petrovich's stake could be worth 300-375 million rubles.

In 2000-2002, Milos Petrovic headed the hospital drug divisions of the representative office of F. Hoffmann – La Roche Ltd in Russia. In 2005, he took up the post of CEO of Roche Moscow and head of the representative office of Roche in Russia. Petrovich left his position in 2014.

In 2009, KhimRar of Alexander Ivaschenko acquired the rights to elsulfavirine from Roche. In 2017, the drug was registered in Russia under the TN Elpida, and in 2019, after the announcement of localization of production at the facilities of Pharmstandard, it was included in the list of vital and essential drugs and the procurement schedule of the Ministry of Health. In 2022, the drug Elpida Combi (tenofovir + elsulfavirine + emtricitabine) was registered. In 2024, the Federal Center for Prevention and Prevention of Diseases purchased Elpida for 6.6 billion rubles, Elpida Combi for 3.9 billion rubles.

Founded in 2009, Elpida (formerly Viriom) is part of the KhimRar Group, which owns 44% of the shares. In 2018, Andrey Reus (5%) and Evgeny Maksimov (7.5%) became co-owners of the company. Reus worked as deputy head of the Ministry of Industry and Trade Viktor Khristenko, and Maksimov owned the Center for Plastic and Endoscopic Surgery (liquidated in 2019), founded by Natalia Manturova, the wife of Denis Manturov, who at that time was the head of the Ministry of Industry and Trade (now the first deputy prime minister). A little later, it was announced that Elpida production would be transferred to the facilities of Pharmstandard, which received a 30% stake in the company in 2019. According to SPARK-Interfax, Elpida LLC earned 6.9 billion rubles in 2024 with a net profit of 3.3 billion.